Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,753
datasets available to search
ShareScore release 0.9.0
Dataset results
2,753 results for “NSCLC”
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT00391274. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NS
ClinicalTrials.gov study NCT03625323. IPD Sharing: NO. Countries: 1. Publications: 1.
Data from: Pre- and post- treatment fold change plasma proteomics in metastatic NSCLC patients
Open the record for dataset details and reuse information.
Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
<p>Wallen ZD, Ko H, Nesline MK, Tierno M, Roos A, Schnettler E, Husain H, Sathyan P, Caveney B, Eisenberg M, Severson EA, Ramkissoon SH. <strong>Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic.</strong> <em>Front Oncol.</em> 2024 Nov 5;14:1473327. doi: <a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1473327">10.3389/fonc.2024.1473327</a>.</p> <p><strong>ABSTRACT</strong></p> <p><strong>Introduction: </strong>Matching patients to an effective targeted therapy or immunotherapy is a challenge for <br>advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one <br>marker at a time. Unlike traditional single marker tests, comprehensive genomic profiling (CGP) can <br>simultaneously assess NSCLC tumors for hundreds of genomic biomarkers and markers for immunotherapy <br>response, leading to quicker and more precise matches to therapeutics. <strong>Methods: </strong>In this study, we performed <br>CGP on 7,606 patients with advanced or metastatic NSCLC using the Illumina TruSight Oncology 500 (TSO <br>500) CGP assay to show its coverage and utility in detecting known and novel features of NSCLC. <strong>Results: </strong><br>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and <br>detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations <br>between genomic alterations and immunotherapy markers were observed including significantly lower TMB <br>levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, <br>MET, BRAF, or ROS1 driver mutations. Co-occurrence analysis followed by network analysis with gene <br>module detection revealed known and novel co-occurrences between genomic alterations. Further, certain <br>modules of genes with co-occurring genomic alterations had dose-dependent relationships with histology and <br>increasing or decreasing levels of PD-L1 and TMB, suggesting a complex relationship between PD-L1, TMB, <br>and genomic alterations in these gene modules. <strong>Discussion:</strong> This study is the largest clinical study to date <br>utilizing the TSO 500. It provides an opportunity to further characterize the landscape of NSCLC using this <br>newer technology and show its clinical utility in detecting known and novel facets of NSCLC to inform treatment <br>decision-making.</p> <p><strong>DATA AVAILABILITY</strong></p> <p>The data and code presented in the study are deposited in this Zenodo repository, accession number <br>13137232 (<a href="https://zenodo.org/record/13137232">https://zenodo.org/record/13137232</a>). Raw sequencing data were derived from routine clinical testing of real-world patients and cannot be shared publicly. Further data inquiries can be directed to the corresponding <br>author. </p>
Supplementary videos for Special issue_Cancers_A New Era in Treatment of Early-stage NSCLC_Takuya Watanabe
<p>Dear Editorial Office</p> <p>Please extrapolate to the manuscript as supplementary videos (Supplementary Video1-5). Thank you very much.</p> <p> </p> <p>Takuya Watanabe</p>
Serum miRnome Profiling: A Novel Biomarker Platform for the Early Detection of NSCLC
<p>Table S1: DEmiRNAs between cancerous and non-cancerous patients; Table S2: Shared DE miRNAs between subgroups; Table S3: NSCLC vs control_GO_BP_results; Table S4: NSCLC vs control_GO_CC_results; Table S5: NSCLC vs control_GO_MF_results; Table S6: NSCLC vs control_KEGG_results.</p>
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
ClinicalTrials.gov study NCT07330596. IPD Sharing: NO. Countries: 1. Publications: 9.
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
ClinicalTrials.gov study NCT05245071. IPD Sharing: YES. Countries: 7. Publications: 0.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
ClinicalTrials.gov study NCT06357533. IPD Sharing: YES. Countries: 21. Publications: 0.
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
ClinicalTrials.gov study NCT06194448. IPD Sharing: YES. Countries: 9. Publications: 1.
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT00874107. IPD Sharing: Not stated. Countries: 2. Publications: 2.
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
ClinicalTrials.gov study NCT02974725. IPD Sharing: NO. Countries: 11. Publications: 2.
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
ClinicalTrials.gov study NCT05583188. IPD Sharing: NO. Countries: 1. Publications: 2.
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
ClinicalTrials.gov study NCT02273375. IPD Sharing: NO. Countries: 19. Publications: 0.
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
ClinicalTrials.gov study NCT04136535. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
ClinicalTrials.gov study NCT06951464. IPD Sharing: YES. Countries: 1. Publications: 1.
Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC
ClinicalTrials.gov study NCT02718365. IPD Sharing: NO. Countries: 1. Publications: 5.
Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT00600587. IPD Sharing: Not stated. Countries: 1. Publications: 7.
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)
ClinicalTrials.gov study NCT03126799. IPD Sharing: NO. Countries: 1. Publications: 1.
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
ClinicalTrials.gov study NCT04808752. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.